The German Breast Group conducts research into breast cancer, developing and implementing its own study concepts.
With the help of additional scientific research projects, we strive to gain further insights into this disease.
A translational study investigating androgen receptor expression in breast cancer patients receiving neoadjuvant chemotherapy from the TECHNO and PREPARE trials has been published in the British Journal of Cancer.
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
Results of a retrospective pooled analysis from three randomized neoadjuvant GBG trials (GeparTrio, GeparQuattro and GeparQuinto) evaluating the impact of post-mastectomy RT (PMRT) after NACT on survival in breast cancer patients have been published in the Annals of Surgical Oncology.
Daten einiger GBG Forschungsprojekte werden beim ESMO 2019 vom 27. September bis 1. Oktober in Barcelona vorgestellt.
Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
Every month, we present an interesting paper.
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440